Pet Wipes Cleaning Experiment for Eye Stains

Pet Wipes Cleaning Efficacy Testing for Eye Stains – Objective Performance Evaluation for Canine and Feline Ocular Discharge Removal

As an ISO/IEC 17025 accredited contract research laboratory, we offer specialised efficacy and safety testing services for pet wipes designed to clean eye stains and tear stains in dogs and cats, serving Bulgarian and international manufacturers, private‑label brands, and veterinary product distributors. Eye stains – reddish‑brown discolouration around the eyes caused by porphyrins, bacteria, yeast, and tear film components – are a common cosmetic and hygiene concern for companion animal owners. Pet wipes formulated for eye area cleaning must demonstrate effective removal of stain‑causing deposits while being gentle on sensitive periocular skin and the ocular surface. Our test protocols combine in vitro stain removal assays, ex vivo porcine skin adhesion studies, and in vivo (or veterinarian‑supervised) patch tests on dogs and cats to assess cleaning power, mildness, and safety. All methods are aligned with ISO 10993 (biological evaluation of medical devices), OECD Guidelines for dermal and ocular safety, and Cosmetics Europe efficacy testing guidelines. Our reports are recognised by the Bulgarian Food Safety Agency (BFSA), veterinary regulatory authorities, and major pet product retailers for product claim substantiation and market entry.

Test Materials and Product Formats We Evaluate

Our laboratory handles a variety of pet wipe formulations and packaging types. Typical test articles include:

• Pre‑moistened wipes for periocular cleaning – with non‑woven substrates (viscose, polyester, cotton) and various wetting solutions
• Tear‑stain removing wipes – containing mild surfactants, chelating agents (EDTA), and optical brighteners
• Antimicrobial wipes – with chlorhexidine, hypochlorous acid, or plant‑based active ingredients (e.g., colloidal silver, aloe vera)
• pH‑balanced and fragrance‑free formulations – for sensitive or allergy‑prone animals
• Hypoallergenic and preservative‑free wipes – for veterinary clinical use
• Wipes with moisturising and soothing ingredients – containing chamomile, green tea, or hyaluronic acid
• Recyclable and biodegradable wipe substrates – for eco‑friendly positioning

In Vitro Cleaning Efficacy – Stain Removal and Soil Dispersion Tests

• Artificial tear‑stain substrate preparation – We prepare standardised stain mimics containing porphyrin (from bovine blood), protein (albumin), lipid (oleic acid), and bacterial growth medium to simulate real tear‑stain deposits. The mixture is applied to glass slides, porcelain plates, or synthetic skin substrates (e.g., VITRO‑SKIN™) and dried at 37 °C for 24 hours to create a reproducible stain layer.
• Wipe application and cleaning protocol – We apply the pet wipe (as‑is, or with a fixed number of strokes – typically 10, 20, or 30 wipes under controlled pressure) to the stained substrate. The number of passes and pressure are standardised using a mechanical wiping apparatus (e.g., a linear abraser or a weight‑loaded sled) to eliminate operator variability. The cleaning process is performed at 23 °C and 50 % RH.
• Quantitative stain removal measurement – Before and after wiping, we measure the reflectance (at 460 nm, 570 nm, and 650 nm) or the colour difference (ΔE* using CIELAB coordinates) of the stain. The Stain Removal Index (SRI) is calculated as: SRI (%) = [(ΔE*_initial – ΔE*_final) / ΔE*_initial] × 100. A high SRI (> 80 %) indicates excellent cleaning performance.
• Residual stain and surface residue analysis – After wiping, we examine the substrate for residual stain using UV light (for porphyrin fluorescence) and high‑resolution digital microscopy. The percentage of residual stain area (by image analysis) is reported.
• Dispersion and emulsification tests – We also assess the ability of the wipe’s wetting solution to disperse the stain components (porphyrin, protein, lipid) by mixing the solution with the stain mimic and measuring turbidity (Nephelometry) after 1, 5, and 15 minutes. A high dispersion rate correlates with easy stain removal and less smearing.

Ex Vivo Stain Removal – Porcine Skin Model (Simulating Periocular Tissue)

• Ex vivo skin preparation – We use freshly excised porcine skin (dorsal or ear) as a surrogate for canine/feline periocular skin. The skin is cleaned, shaved, and dried, then standardised stain deposits are applied to 2×2 cm areas (50 µL of stain mimic) and allowed to dry for 2 hours at ambient conditions.
• Wipe application and cleaning – The pet wipe is manually applied to the stained area with a controlled number of passes (10, 20, or 30) and a uniform pressure (using a load of 100 g). Cleaning is performed under 23 °C, 50 % RH, and the process is video‑recorded for consistency.
• Cleaning efficiency assessment – After cleaning, we wash the skin with a gentle buffer, extract residual stain components, and quantify them using spectrophotometry (for porphyrin) and protein assay (BCA method). The percentage removal of porphyrin and protein is calculated. A removal of ≥ 85 % for both components is considered excellent.
• Skin integrity and irritation after wiping – After the wiping process, we evaluate the skin for erythema, oedema, and barrier function (transepidermal water loss – TEWL) using a TEWL meter. A TEWL increase of < 10 % from baseline indicates minimal skin disruption.
• Visual and microscopic assessment – We photograph the skin surface before, during, and after wiping, and examine the microstructure under a dermatoscope (10‑50×) to detect any mechanical damage (e.g., excoriation, abrasion, or follicular swelling).

In Vivo Safety and Mildness – Patch Testing and Repeat‑Insult on Dogs and Cats

• Repeat Insult Patch Test (RIPT) on dogs – We conduct a modified RIPT in a cohort of healthy dogs (n=10‑15) with normal periocular skin. The pet wipe is applied to a shaved area (4 cm²) on the lateral thorax using an occlusive patch for 24 hours, repeated 3 times per week over 3 weeks. We score erythema, oedema, and papule formation at 0, 24, 48, and 72 hours after each application, using a 0‑4 scale. A cumulative irritation index ≤ 1.0 is considered non‑irritating.
• Ocular safety in dogs (modified Draize) – In a separate group (n=3‑5 dogs), we instil a small volume (0.05 mL) of the wipe’s wetting solution into the conjunctival sac of one eye; the contralateral eye receives sterile saline as control. Corneal and conjunctival changes are scored at 1, 4, 24, 48, and 72 hours. Products with a score of ≤ 5 (out of 110) are classified as non‑irritating.
• Cat‑specific sensitivity assessment – Because cats are more sensitive to certain preservatives (e.g., benzalkonium chloride) and essential oils, we perform a separate patch test in cats (n=5‑8). The wipe is applied to the shaved flank for 2 hours, and reactions are scored at 1, 4, 24, and 48 hours. A score of ≤ 1 (very slight erythema) is required for feline products.
• Eye area cleaning test – real‑world efficacy – Under veterinary supervision, we test the pet wipe on the periocular area of dogs and cats with visible tear stains for 7‑14 days (once daily). We photograph the area (standardised lighting, angle, and distance) before, during, and after treatment, and use image analysis software to quantify the reduction in stain area (%). The stain area reduction is reported as mean ± SD, and the number of animals achieving ≥ 50 % reduction is documented.
• Owner satisfaction and acceptance – We collect subjective feedback from pet owners regarding ease of use, wipe texture, wetness, fragrance, and any adverse events (redness, squinting, scratching). A satisfaction score of ≥ 8 out of 10 is considered a positive outcome.

Microbiological Safety – Contamination and Preservative Efficacy

• Preservative Efficacy Test (PET) – USP <51> / ISO 11930 – We challenge the wipe product with standard microorganisms: Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Candida albicans, and Aspergillus brasiliensis. The product is inoculated and sampled at 0, 7, 14, and 28 days; a log reduction of ≥ 2 for bacteria (within 14 days) and ≥ 1 for fungi (within 14 days) is required for compliance with EU and Bulgarian cosmetic/medical device standards.
• Stability and shelf‑life testing – ASTM F1980 / ISO 11607 – We perform accelerated ageing (40 °C and 75 % RH for 6 months, and 50 °C and 80 % RH for 3 months) on sealed wipe packages and test for preservative concentration, pH, and microbial load at intervals. A shelf‑life of ≥ 2 years is typically demonstrated.
• Heavy metal and impurity screening – ISO 17294 / USP <232> – Using ICP‑MS, we analyse the wetting solution for lead, cadmium, mercury, arsenic, and other impurities to ensure safety for periocular use. Limits are set per EU cosmetic regulations (≤ 1 ppm for lead, ≤ 0.5 ppm for cadmium, etc.).

Skin Microbiome Compatibility – Safety of Indigenous Flora

• Selective antibacterial activity – We test the pet wipe’s wetting solution against typical canine/feline skin commensals (e.g., Staphylococcus pseudintermedius, Staphylococcus felis, Micrococcus luteus) and potential pathogens (Malassezia pachydermatis, Pseudomonas aeruginosa) using broth microdilution (CLSI M07‑A11). The minimum inhibitory concentration (MIC) is determined; a MIC > 500 µg/mL against commensals and < 200 µg/mL against pathogens indicates a favourable selectivity.
• Cytotoxicity to primary skin cells – ISO 10993‑5 (MTT assay) – We culture primary canine and feline fibroblasts and expose them to various dilutions of the wetting solution. The IC₅₀ is determined; a value of IC₅₀ > 300 µg/mL is considered non‑cytotoxic.
• Skin hydration and barrier function – in vivo evaluation – In the canine patch test, we measure stratum corneum hydration (Corneometer) and TEWL (Tewameter) before and after 14 days of daily application. An increase in hydration of ≥ 10 % and no significant change in TEWL indicate skin compatibility.

Regulatory Compliance and Claim Substantiation

All efficacy and safety tests described above are performed under our ISO/IEC 17025 accreditation and in compliance with Good Laboratory Practice (GLP) where applicable. Our final reports provide a comprehensive dataset including: in vitro cleaning efficacy (SRI and colour difference), ex vivo removal percentages, in vivo safety scores (patch test, ocular irritation), real‑world stain reduction (by image analysis), microbiological preservation data, and cytotoxicity results. We also provide a summary of statistical comparisons (t‑tests or ANOVA) and a clear conclusion on whether the product supports the claim “effectively removes eye stains” and “safe for periocular use”. These reports are accepted by BFSA, ECHA, and Bulgarian pet product retailers for regulatory filing, label claims, and marketing authorisation. Bilingual (Bulgarian/English) versions are available for ease of submission.